VINFOSILTINE SULFATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C51H72N5O10P.H2O4S
Molecular Weight	1044.197
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.[H][C@@]12N3CC[C@@]14C5=C(C=C(OC)C(=C5)[C@]6(C[C@@]7([H])CN(C[C@](O)(CC)C7)CCC8=C6NC9=C8C=CC=C9)C(=O)OC)N(C)[C@@]4([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)N[C@H](C(C)C)P(=O)(OCC)OCC

InChI

InChIKey=BZUUMJJIORUJAU-DVQOEFLDSA-N

InChI=1S/C51H72N5O10P.H2O4S/c1-10-47(60)27-32-28-50(46(59)64-9,40-34(19-23-55(29-32)30-47)33-17-14-15-18-37(33)52-40)36-25-35-38(26-39(36)63-8)54(7)43-49(35)21-24-56-22-16-20-48(11-2,42(49)56)44(57)51(43,61)45(58)53-41(31(5)6)67(62,65-12-3)66-13-4;1-5(2,3)4/h14-18,20,25-26,31-32,41-44,52,57,60-61H,10-13,19,21-24,27-30H2,1-9H3,(H,53,58);(H2,1,2,3,4)/t32-,41-,42-,43+,44+,47-,48+,49+,50-,51-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C51H72N5O10P
Molecular Weight	946.1186
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7882462

Vinfosiltine (also known as S 12363) was developed as a vinca alkaloid derivative. It is known that vinca alkaloids are widely used in the medical treatment of breast cancer. Vinfosiltine participated in the phase II clinical trial to treat the patients with advanced breast cancer. The results have shown that the drug didn’t have significant single-agent activity. As a result, the development of vinfosiltine was discontinued.

Approval Year

PubMed

Title	Date	PubMed
Evaluation of the time-schedule dependency for the cytotoxic activity of the new vinca alkaloid derivative, S 12363 (vinfosiltine).	1993	8260248
Phase II study of a new vinca alkaloid derivative, S12363, in advanced breast cancer.	1995	7882462

Sample Use Guides

In Vivo Use Guide

a randomization was performed between two schedules with the same dose intensity, that is, 0.3 mg/m2 given weekly or 0.6 mg/m2 given every 2 weeks

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:11:41 GMT 2023` Edited by `admin` on `Sat Dec 16 16:11:41 GMT 2023`
Record UNII	JT6020N64H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VINFOSILTINE SULFATE

Common Name

English

VINCALEUKOBLASTINE, O4-DEACETYL-3-DE(METHOXYCARBONYL)-3-(((1-(DIETHOXYPHOSPHINYL)-2-METHYLPROPYL)AMINO)CARBONYL)-, (3(S))-, SULFATE (1:1) (SALT)

Systematic Name

English

S 12363

Code

English

S-12363

Code

English

S12363

Code

English

Code System Code Type Description

FDA UNII

JT6020N64H